Skip to main content
Journal cover image

Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.

Publication ,  Journal Article
Smith, DC; Vick, NA; Trump, DL; Friedman, HS; Friedman, AH; Purvis, J; Gauspari, A; Schold, SC
Published in: Cancer Chemother Pharmacol
1992

On the basis of response rates of up to 50%, BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea] is the primary drug used in the chemotherapy of anaplastic gliomas. Preclinical data obtained in several experimental systems show that the cytotoxicity of chloroethylnitrosoureas can be increased by the concomitant use of thiopurines. In this phase I trial, patients with anaplastic gliomas received standard-dose BCNU (200 mg/m2 x 1) in combination with escalating doses of intravenous 6-mercaptopurine (200, 350, 500, and 750 mg/m2 daily x 3), with BCNU being given on day 3 to maximize the effect of the drugs on cellular DNA. No increase in hematologic toxicity was demonstrated as the dose of 6-mercaptopurine was increased. Responses and stabilization of disease were observed in several patients. Due to the safety of and the evidence of activity found for this regimen in the present trial, 750 mg/m2 6-mercaptopurine has been incorporated into subsequent studies.

Duke Scholars

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1992

Volume

30

Issue

4

Start / End Page

272 / 276

Location

Germany

Related Subject Headings

  • Oncology & Carcinogenesis
  • Middle Aged
  • Mercaptopurine
  • Male
  • Injections, Intravenous
  • Humans
  • Glioma
  • Female
  • Drug Synergism
  • Drug Evaluation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Smith, D. C., Vick, N. A., Trump, D. L., Friedman, H. S., Friedman, A. H., Purvis, J., … Schold, S. C. (1992). Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. Cancer Chemother Pharmacol, 30(4), 272–276. https://doi.org/10.1007/BF00686294
Smith, D. C., N. A. Vick, D. L. Trump, H. S. Friedman, A. H. Friedman, J. Purvis, A. Gauspari, and S. C. Schold. “Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.Cancer Chemother Pharmacol 30, no. 4 (1992): 272–76. https://doi.org/10.1007/BF00686294.
Smith DC, Vick NA, Trump DL, Friedman HS, Friedman AH, Purvis J, et al. Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. Cancer Chemother Pharmacol. 1992;30(4):272–6.
Smith, D. C., et al. “Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.Cancer Chemother Pharmacol, vol. 30, no. 4, 1992, pp. 272–76. Pubmed, doi:10.1007/BF00686294.
Smith DC, Vick NA, Trump DL, Friedman HS, Friedman AH, Purvis J, Gauspari A, Schold SC. Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. Cancer Chemother Pharmacol. 1992;30(4):272–276.
Journal cover image

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1992

Volume

30

Issue

4

Start / End Page

272 / 276

Location

Germany

Related Subject Headings

  • Oncology & Carcinogenesis
  • Middle Aged
  • Mercaptopurine
  • Male
  • Injections, Intravenous
  • Humans
  • Glioma
  • Female
  • Drug Synergism
  • Drug Evaluation